โ NO significant difference in #MASH, #CardiovascularDisease or mortality between lean and non-lean patients with #MASLD.
ย
Donโt be blinded by #obesity -- lean MASLD patients might be slipping under the radar ๐ซฃ
ย
@MapoukaMexan @UMCapitalRegion #ACG2025
https://t.co/HFLVMvtQox
Happy to share our newly published retrospective cohort study, in which we examined national trends in chronic pancreatitis hospitalizations across the United States over time!@SarpB44
#GITweet@AmerGastroAssn@AmCollegeGastro#Pancreatitis#Pancreas
Grateful for the opportunity to collaborate with these GI powerhouses on such an important topic.
Now available online at https://t.co/NufloLBQd6
#GITwitter#MedTwitter
Congratulations @MapoukaMexan on leading this project ๐๐พ
โ๏ธ MA of 10M+ pts
โ๏ธ Non-lean (vs lean) MASLD patients have ๐ odds of fibrosis, steatosis, cirrhosis & HTN
โ๏ธ Risk of MASH, CVD, & mortality similar in both groups
๐ Screenx should go beyond BMI alone
#GITwitter#MASLD
Happy to share our newly published paper in the World Journal of Gastroenterology.
Please take a look at our findings exploring the differences in liver and cardiovascular metabolic disease outcomes between lean and non-lean MASLD patients.
Thanks to all the co-authors for their valuable contributions! @NkengehNTD #GITwitter #MedTwitter
https://t.co/3avO6emz2j
๐จ New publication
Can AI improve the cost-effectiveness of screening for advanced fibrosis in MASLD?
Our latest study shows AI risk stratification + elastography outperforms traditional FIB-4โbased screening, delivering greater gains at favorable cost-effectiveness thresholds.
๐https://t.co/lbqJFqHkBi
#MASLD #Hepatology #ArtificialIntelligence #HealthEconomics
Excited to share our newly published article in @GIE_Journal
https://t.co/R9zjzKuYMP
Very thankful for the amazing mentorship of @SamIgbinedion and our wonderful team.
#GITwitter#Medtwitter
Happy to share our latest published work in @GIE_Journal on Upfront Endoscopic Necrosectomy vs. Step-Up Endoscopic Approach for Walled-off Pancreatic Necrosis!
https://t.co/WCXDuklhSM
Thank you @HealioGastro@AmCollegeGastro
Screening, surveillance for MASLD needs to expand ‘beyond BMI’ https://t.co/neUp27WGKd
Please check out our newly published case report on Salmonella presenting beyond the gastrointestinal tract.
https://t.co/CRsCiJj2ZW
@AmCollegeGastro#GITwitter
Excited to have been part of #TLM2025.
Key highlight was the hospitality of everyone I met, esp my co-ELS friends
Grateful to my mentors @LewisRobertsMD & @AkwiAsombangMD for the massive support pre- & post my ELS award; and to @ndshah85 & @AASLDFoundation for this opportunity
๐ฐ Just in from #ACG2025: Non-lean #MASLD patients face higher risk of fibrosis, steatosis & hypertension ๐ their lean counterparts.
ย
๐จ๏ธ โ#Obesity shouldnโt be the sole criterion for MASLD screening,โ says @MapoukaMexan @UMCapitalRegion.
https://t.co/HFLVMvtQox
I am so grateful for giving my oral presentation #ACG2025 today! And here are some key take away points: lean patients with MASLD may have same outcomes risk level of MASH (former NASH), cardiovascular diseases and mortality compared to non-lean MASLD in large pooled estimates!
There is a need to develop risk stratification for lean MASLD patients.
Thank you so much @AmCollegeGastro@ACG_CTG@AAFG_2021 #GITwitter @HealioGastro and to the moderators and those who attended!